107 related articles for article (PubMed ID: 31142511)
1. The Pro-Oncogenic Adaptor CIN85 Acts as an Inhibitory Binding Partner of Hypoxia-Inducible Factor Prolyl Hydroxylase 2.
Kozlova N; Mennerich D; Samoylenko A; Dimova EY; Koivunen P; Biterova E; Richter K; Hassinen A; Kellokumpu S; Manninen A; Miinalainen I; Glumoff V; Ruddock L; Drobot LB; Kietzmann T
Cancer Res; 2019 Aug; 79(16):4042-4056. PubMed ID: 31142511
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-inducible factor prolyl hydroxylase 2 (PHD2) is a direct regulator of epidermal growth factor receptor (EGFR) signaling in breast cancer.
Kozlova N; Wottawa M; Katschinski DM; Kristiansen G; Kietzmann T
Oncotarget; 2017 Feb; 8(6):9885-9898. PubMed ID: 28038470
[TBL] [Abstract][Full Text] [Related]
3. Expression and DNA methylation levels of prolyl hydroxylases PHD1, PHD2, PHD3 and asparaginyl hydroxylase FIH in colorectal cancer.
Rawluszko AA; Bujnicka KE; Horbacka K; Krokowicz P; Jagodziński PP
BMC Cancer; 2013 Nov; 13():526. PubMed ID: 24195777
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-alpha-prolyl-4-hydroxylases.
Marxsen JH; Stengel P; Doege K; Heikkinen P; Jokilehto T; Wagner T; Jelkmann W; Jaakkola P; Metzen E
Biochem J; 2004 Aug; 381(Pt 3):761-7. PubMed ID: 15104534
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-inducible factor prolyl-4-hydroxylase PHD2 protein abundance depends on integral membrane anchoring of FKBP38.
Barth S; Edlich F; Berchner-Pfannschmidt U; Gneuss S; Jahreis G; Hasgall PA; Fandrey J; Wenger RH; Camenisch G
J Biol Chem; 2009 Aug; 284(34):23046-58. PubMed ID: 19546213
[TBL] [Abstract][Full Text] [Related]
6. miR-21 contributes to renal protection by targeting prolyl hydroxylase domain protein 2 in delayed ischaemic preconditioning.
Jiao X; Xu X; Fang Y; Zhang H; Liang M; Teng J; Ding X
Nephrology (Carlton); 2017 May; 22(5):366-373. PubMed ID: 27030384
[TBL] [Abstract][Full Text] [Related]
7. Defective Tibetan PHD2 binding to p23 links high altitude adaption to altered oxygen sensing.
Song D; Li LS; Arsenault PR; Tan Q; Bigham AW; Heaton-Johnson KJ; Master SR; Lee FS
J Biol Chem; 2014 May; 289(21):14656-65. PubMed ID: 24711448
[TBL] [Abstract][Full Text] [Related]
8. Gambogic acid inhibits angiogenesis through inhibiting PHD2-VHL-HIF-1α pathway.
Lu N; Hui H; Yang H; Zhao K; Chen Y; You QD; Guo QL
Eur J Pharm Sci; 2013 May; 49(2):220-6. PubMed ID: 23501055
[TBL] [Abstract][Full Text] [Related]
9. Intermediary metabolite precursor dimethyl-2-ketoglutarate stabilizes hypoxia-inducible factor-1α by inhibiting prolyl-4-hydroxylase PHD2.
Hou P; Kuo CY; Cheng CT; Liou JP; Ann DK; Chen Q
PLoS One; 2014; 9(11):e113865. PubMed ID: 25420025
[TBL] [Abstract][Full Text] [Related]
10. Identification of Small-Molecule PHD2 Zinc Finger Inhibitors that Activate Hypoxia Inducible Factor.
Arsenault PR; Song D; Bergkamp M; Ravaschiere AM; Navalsky BE; Lieberman PM; Lee FS
Chembiochem; 2016 Dec; 17(24):2316-2323. PubMed ID: 27770548
[TBL] [Abstract][Full Text] [Related]
11. The adaptor protein Ruk/CIN85 activates plasminogen activator inhibitor-1 (PAI-1) expression via hypoxia-inducible factor-1alpha.
Samoylenko A; Dimova EY; Kozlova N; Drobot L; Kietzmann T
Thromb Haemost; 2010 May; 103(5):901-9. PubMed ID: 20216986
[TBL] [Abstract][Full Text] [Related]
12. Knockdown of prolyl-4-hydroxylase domain 2 inhibits tumor growth of human breast cancer MDA-MB-231 cells by affecting TGF-β1 processing.
Wottawa M; Leisering P; Ahlen Mv; Schnelle M; Vogel S; Malz C; Bordoli MR; Camenisch G; Hesse A; Napp J; Alves F; Kristiansen G; Farhat K; Katschinski DM
Int J Cancer; 2013 Jun; 132(12):2787-98. PubMed ID: 23225569
[TBL] [Abstract][Full Text] [Related]
13. PHD1 interacts with ATF4 and negatively regulates its transcriptional activity without prolyl hydroxylation.
Hiwatashi Y; Kanno K; Takasaki C; Goryo K; Sato T; Torii S; Sogawa K; Yasumoto K
Exp Cell Res; 2011 Dec; 317(20):2789-99. PubMed ID: 21951999
[TBL] [Abstract][Full Text] [Related]
14. The roles and signaling pathways of prolyl-4-hydroxylase 2 in the tumor microenvironment.
Li A; Zhang Y; Wang Z; Dong H; Fu N; Han X
Chem Biol Interact; 2019 Apr; 303():40-49. PubMed ID: 30817904
[TBL] [Abstract][Full Text] [Related]
15. Regulation of HIF prolyl hydroxylases by hypoxia-inducible factors.
Aprelikova O; Chandramouli GV; Wood M; Vasselli JR; Riss J; Maranchie JK; Linehan WM; Barrett JC
J Cell Biochem; 2004 Jun; 92(3):491-501. PubMed ID: 15156561
[TBL] [Abstract][Full Text] [Related]
16. The peptidyl prolyl cis/trans isomerase FKBP38 determines hypoxia-inducible transcription factor prolyl-4-hydroxylase PHD2 protein stability.
Barth S; Nesper J; Hasgall PA; Wirthner R; Nytko KJ; Edlich F; Katschinski DM; Stiehl DP; Wenger RH; Camenisch G
Mol Cell Biol; 2007 May; 27(10):3758-68. PubMed ID: 17353276
[TBL] [Abstract][Full Text] [Related]
17. Prolyl hydroxylase domain 2 protein suppresses hypoxia-induced endothelial cell proliferation.
Takeda K; Fong GH
Hypertension; 2007 Jan; 49(1):178-84. PubMed ID: 17101841
[TBL] [Abstract][Full Text] [Related]
18. DNA methylation analysis of the HIF-1α prolyl hydroxylase domain genes PHD1, PHD2, PHD3 and the factor inhibiting HIF gene FIH in invasive breast carcinomas.
Huang KT; Mikeska T; Dobrovic A; Fox SB
Histopathology; 2010 Sep; 57(3):451-60. PubMed ID: 20727020
[TBL] [Abstract][Full Text] [Related]
19. Prolyl hydroxylase domain 2 deficiency promotes skeletal muscle fiber-type transition via a calcineurin/NFATc1-dependent pathway.
Shin J; Nunomiya A; Kitajima Y; Dan T; Miyata T; Nagatomi R
Skelet Muscle; 2016; 6():5. PubMed ID: 26949511
[TBL] [Abstract][Full Text] [Related]
20. Prolyl hydroxylase-2 (PHD2) exerts tumor-suppressive activity in pancreatic cancer.
Su Y; Loos M; Giese N; Metzen E; Büchler MW; Friess H; Kornberg A; Büchler P
Cancer; 2012 Feb; 118(4):960-72. PubMed ID: 21792862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
